SAROS changes https://saros.gcarosso.bio/ Registry and regulatory changes since the 2026-11-01 snapshot: slipped, firmed and new trials, status changes, moved PDUFA dates. Public sources only. 2026-11-03T15:37:36.214689Z CHANGED · FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenochttps://saros.gcarosso.bio/#t=NCT06303505NCT06303505:changed:2026-11-03Gilead Sciences · enrollment: 250 → 334; primary outcome text: Phase 1: Percentage of Participants Experiencing any Dose-limiting Toxicities (DLTs)[ → Phase 1: Percentage of Participants Experiencing any Dose-limiting Toxicities (DLTs) CHANGED · Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIhttps://saros.gcarosso.bio/#t=NCT05327114NCT05327114:changed:2026-11-03Janssen Research & Development, LLC · primary completion: 2027-05-14 → 2026-12-15 STATUS · A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasmshttps://saros.gcarosso.bio/#t=NCT06618001NCT06618001:status:2026-11-03Janssen Research & Development, LLC · primary completion: 2026-09-02 → 2026-09-01; status: ACTIVE_NOT_RECRUITING → COMPLETED NEW · A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)https://saros.gcarosso.bio/#t=NCT07157254NCT07157254:new:2026-11-03Ultragenyx Pharmaceutical Inc · new in the registry NEW · Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)https://saros.gcarosso.bio/#t=NCT07913347NCT07913347:new:2026-11-03Metagen Therapeutics, Inc. · new in the registry NEW · Bioequivalence Study Between YHP2508A and YHR2601 in Healthy Subjectshttps://saros.gcarosso.bio/#t=NCT07912827NCT07912827:new:2026-11-03Yuhan Corporation · new in the registry FIRMED · Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-rehttps://saros.gcarosso.bio/#t=NCT07059767NCT07059767:firmed:2026-11-03Ethris GmbH · primary completion: 2026-06 → 2026-09-01; date type: ESTIMATED → ACTUAL; status: RECRUITING → COMPLETED STATUS · A Study to Assess the Bioavailability and Adhesion of Estradiol/Levonorgestrel TDS in Healthy Post-Menopausal https://saros.gcarosso.bio/#t=NCT07851649NCT07851649:status:2026-11-03Corium Innovations, Inc. · primary completion: 2026-09-08 → 2026-09-29; status: ACTIVE_NOT_RECRUITING → COMPLETED NEW · A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Ihttps://saros.gcarosso.bio/#t=NCT07913061NCT07913061:new:2026-11-03Jiangsu HengRui Medicine Co., Ltd. · new in the registry STATUS · A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negativehttps://saros.gcarosso.bio/#t=NCT07827573NCT07827573:status:2026-11-03Hoffmann-La Roche · status: NOT_YET_RECRUITING → RECRUITING STATUS · Opt-IVF for Personalized Medicine for Normal Respondershttps://saros.gcarosso.bio/#t=NCT07856082NCT07856082:status:2026-11-03Urmila DIwekar · status: RECRUITING → ACTIVE_NOT_RECRUITING NEW · A Study of MBS314 for Injectionin Participants With Relapsed/Refractory Multiple Myeloma.https://saros.gcarosso.bio/#t=NCT07911748NCT07911748:new:2026-11-03Beijing Mabworks Biotech Co., Ltd. · new in the registry SLIPPED · A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumorshttps://saros.gcarosso.bio/#t=NCT05773820NCT05773820:slipped:2026-11-03Wigen Biomedicine Technology (Shanghai) Co., Ltd. · primary completion: 2026-08-08 → 2027-12-31; status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 210 → 63 FIRMED · A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Phttps://saros.gcarosso.bio/#t=NCT02494986NCT02494986:firmed:2026-11-03Janssen Sciences Ireland UC · date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → COMPLETED FIRMED · A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infectionhttps://saros.gcarosso.bio/#t=NCT06903338NCT06903338:firmed:2026-11-03Vir Biotechnology, Inc. · primary completion: 2026-12-31 → 2026-09-30; date type: ESTIMATED → ACTUAL FIRMED · A Study to Learn How ASP3082 is Processed in Healthy Menhttps://saros.gcarosso.bio/#t=NCT07773129NCT07773129:firmed:2026-11-03Astellas Pharma Global Development, Inc. · primary completion: 2026-10-31 → 2026-10-20; date type: ESTIMATED → ACTUAL; status: RECRUITING → COMPLETED NEW · GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorecthttps://saros.gcarosso.bio/#t=NCT07913360NCT07913360:new:2026-11-03Genfleet Therapeutics (Shanghai) Inc. · new in the registry NEW · Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinomahttps://saros.gcarosso.bio/#t=NCT07911683NCT07911683:new:2026-11-03BeOne Medicines · new in the registry STATUS · Phase Ia Study of MST-931 in Healthy Adult Subjectshttps://saros.gcarosso.bio/#t=NCT07903493NCT07903493:status:2026-11-03Mabsoft Therapeutics (Shanghai) Co., Ltd. · status: NOT_YET_RECRUITING → RECRUITING SLIPPED · Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)https://saros.gcarosso.bio/#t=NCT07224360NCT07224360:slipped:2026-11-03CSL Behring · primary completion: 2028-06-29 → 2028-08-15 NEW · Rimonabant for Improving Walking Ability in Patients With Chronic Strokehttps://saros.gcarosso.bio/#t=NCT07913763NCT07913763:new:2026-11-03Sinfatin S.L · new in the registry FIRMED · Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participantshttps://saros.gcarosso.bio/#t=NCT07685600NCT07685600:firmed:2026-11-03AstraZeneca · primary completion: 2026-10-28 → 2026-10-22; date type: ESTIMATED → ACTUAL; status: RECRUITING → COMPLETED NEW · Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumorshttps://saros.gcarosso.bio/#t=NCT07912593NCT07912593:new:2026-11-03Ensem Therapeutics · new in the registry NEW · A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Shttps://saros.gcarosso.bio/#t=NCT07911579NCT07911579:new:2026-11-03CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · new in the registry STATUS · A Study of SL-325 in Crohn's Disease Patientshttps://saros.gcarosso.bio/#t=NCT07753850NCT07753850:status:2026-11-03Shattuck Labs, Inc. · status: NOT_YET_RECRUITING → RECRUITING NEW · A Phase Ⅱ Clinical Trial Evaluating the Efficacy and Safety of SYH2072 Tablets In Hypertensive Patientshttps://saros.gcarosso.bio/#t=NCT07911735NCT07911735:new:2026-11-03InnovStone Therapeutics Limited · new in the registry STATUS · Safety, Tolerability And Pharmacodynamics of DM-101PX in Birch Pollen Allergyhttps://saros.gcarosso.bio/#t=NCT07898800NCT07898800:status:2026-11-03Desentum Oy · status: NOT_YET_RECRUITING → RECRUITING FIRMED · A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanhttps://saros.gcarosso.bio/#t=NCT05805501NCT05805501:firmed:2026-11-03Hoffmann-La Roche · primary completion: 2026-10-08 → 2026-10-05; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → COMPLETED STATUS · A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancerhttps://saros.gcarosso.bio/#t=NCT07906717NCT07906717:status:2026-11-03Janssen Research & Development, LLC · status: NOT_YET_RECRUITING → RECRUITING NEW · ARTEMIS: UC-MSCs After Mechanical Thrombectomy for Acute Ischemic Strokehttps://saros.gcarosso.bio/#t=NCT07913282NCT07913282:new:2026-11-03Royan Stem Cell Technology Company · new in the registry STATUS · A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcehttps://saros.gcarosso.bio/#t=NCT07196748NCT07196748:status:2026-11-03Janssen Research & Development, LLC · status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 882 → 896 STATUS · A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food Effect on thttps://saros.gcarosso.bio/#t=NCT07837115NCT07837115:status:2026-11-03Celgene · status: NOT_YET_RECRUITING → RECRUITING STATUS · Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)https://saros.gcarosso.bio/#t=NCT06617429NCT06617429:status:2026-11-03Ultragenyx Pharmaceutical Inc · status: ACTIVE_NOT_RECRUITING → TERMINATED; why stopped: → Lack of efficacy NEW · Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Hepatic Impairmenthttps://saros.gcarosso.bio/#t=NCT07913009NCT07913009:new:2026-11-03Haisco Pharmaceutical Group Co., Ltd. · new in the registry NEW · Phase 3 Study of rhTPO for Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Prohttps://saros.gcarosso.bio/#t=NCT07911800NCT07911800:new:2026-11-03MIBIO PTE. LTD. · new in the registry FIRMED · Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age Whttps://saros.gcarosso.bio/#t=NCT02612454NCT02612454:firmed:2026-11-03Regeneron Pharmaceuticals · primary completion: 2026-10-07 → 2026-10-09; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → COMPLETED STATUS · A Study of Zasocitinib in Adults With Nonsegmental Vitiligohttps://saros.gcarosso.bio/#t=NCT07108283NCT07108283:status:2026-11-03Takeda · primary completion: 2027-10-12 → 2027-03-26; status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 200 → 207 NEW · A Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy Volunteershttps://saros.gcarosso.bio/#t=NCT07909837NCT07909837:new:2026-11-03Nanjing Chia-tai Tianqing Pharmaceutical · new in the registry NEW · Evaluation of LB-208 (HTR1B Antagonist) in Adult Patients With Relapsed or Refractory Solid Tumours and Lymphohttps://saros.gcarosso.bio/#t=NCT07914348NCT07914348:new:2026-11-03Leukos Biotech S.L. · new in the registry SLIPPED · Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Phttps://saros.gcarosso.bio/#t=NCT07276789NCT07276789:slipped:2026-11-03Integro Theranostics · primary completion: 2026-08 → 2027-06; status: RECRUITING → ACTIVE_NOT_RECRUITING CHANGED · An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)https://saros.gcarosso.bio/#t=NCT06961344NCT06961344:changed:2026-11-03Tisento Therapeutics · why stopped: On 5 October 2026 the study was terminated based on results from the parent study, which did not meet its primary or secondary efficacy endpoints. The decision was not related to a safety. → Terminated based on results from the parent study, which did not meet its primary or secondary efficacy endpoints. The decision was not related to a safety. STATUS · A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psorhttps://saros.gcarosso.bio/#t=NCT07321873NCT07321873:status:2026-11-03Janssen Research & Development, LLC · status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 240 → 157 NEW · Study to Compare GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With Recurrent Genital Herpeshttps://saros.gcarosso.bio/#t=NCT07912996NCT07912996:new:2026-11-03Gilead Sciences · new in the registry NEW · A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe https://saros.gcarosso.bio/#t=NCT05676242NCT05676242:new:2026-11-03Suzhou Zelgen Biopharmaceuticals Co.,Ltd · new in the registry NEW · Bioequivalence Study Between YHP2508B and YHR2602 in Healthy Subjectshttps://saros.gcarosso.bio/#t=NCT07912840NCT07912840:new:2026-11-03Yuhan Corporation · new in the registry NEW · A Study for AR100DP1 in Mild to Moderate Atopic Dermatitishttps://saros.gcarosso.bio/#t=NCT07914088NCT07914088:new:2026-11-03Arjil Pharmaceuticals LLC · new in the registry NEW · Long-term Extension of GTX-102 in Angelman Syndromehttps://saros.gcarosso.bio/#t=NCT06415344NCT06415344:new:2026-11-03Ultragenyx Pharmaceutical Inc · new in the registry SLIPPED · Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemiahttps://saros.gcarosso.bio/#t=NCT04716452NCT04716452:slipped:2026-11-03Keystone Nano, Inc · primary completion: 2026-09-30 → 2027-01-30 SLIPPED · Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritishttps://saros.gcarosso.bio/#t=NCT05517980NCT05517980:slipped:2026-11-03Kira Pharmacenticals (US), LLC. · primary completion: 2026-03 → 2028-12; status: NOT_YET_RECRUITING → RECRUITING CHANGED · Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Dishttps://saros.gcarosso.bio/#t=NCT05270525NCT05270525:changed:2026-11-03Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA · enrollment: 56 → 70; primary outcome text: The change from baseline in sputum neutrophils at Week 8 (absolute change in cell numbers) → The Absolute Change From Baseline in Sputum Neutrophil Cell Numbers STATUS · A Study to Determine the Safety and Efficacy of NT-501 With M-CHFMhttps://saros.gcarosso.bio/#t=NCT06397131NCT06397131:status:2026-11-03Neurotech Pharmaceuticals · status: ACTIVE_NOT_RECRUITING → RECRUITING; enrollment: 12 → 60; primary outcome text: Rate of Change in Ellipsoid Zone (EZ) Area Loss → Cohort 1 (Extension) - Efficacy FIRMED · A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjectshttps://saros.gcarosso.bio/#t=NCT07452692NCT07452692:firmed:2026-11-03Corium Innovations, Inc. · primary completion: 2026-10-06 → 2026-09-26; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → COMPLETED NEW · A Study to Evaluate Efficacy, Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine ihttps://saros.gcarosso.bio/#t=NCT07908654NCT07908654:new:2026-11-03Guangzhou Patronus Biotech Co., Ltd. · new in the registry STATUS · A Study of Zasocitinib in Adults With Hidradenitis Suppurativahttps://saros.gcarosso.bio/#t=NCT07244263NCT07244263:status:2026-11-03Takeda · status: RECRUITING → ACTIVE_NOT_RECRUITING STATUS · A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologichttps://saros.gcarosso.bio/#t=NCT06807424NCT06807424:status:2026-11-03Janssen Research & Development, LLC · status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 750 → 813 NEW · Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Chttps://saros.gcarosso.bio/#t=NCT07912268NCT07912268:new:2026-11-03Jiangsu Simcere Pharmaceutical Co., Ltd. · new in the registry STATUS · Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominhttps://saros.gcarosso.bio/#t=NCT06980948NCT06980948:status:2026-11-03Sangamo Therapeutics · status: RECRUITING → SUSPENDED; why stopped: → Study is suspended while Sangamo seeks a new sponsor for the ST-503-101 study NEW · Safety, Tolerability and Pharmacokinetics of ICP-B161 in Healthy Adults Volunteershttps://saros.gcarosso.bio/#t=NCT07911982NCT07911982:new:2026-11-03Beijing InnoCare Pharma Tech Co., Ltd. · new in the registry NEW · A Study to Assess the Safety and Effectiveness of COL-5671-PRO Capsules in Adults With Moderate-to-Severe Plaqhttps://saros.gcarosso.bio/#t=NCT07914231NCT07914231:new:2026-11-03Coultreon Biopharma · new in the registry SLIPPED · Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adultshttps://saros.gcarosso.bio/#t=NCT06862453NCT06862453:slipped:2026-11-03Sanaria Inc. · primary completion: 2026-09-30 → 2027-08-30; enrollment: 58 → 42 NEW · A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolohttps://saros.gcarosso.bio/#t=NCT07913074NCT07913074:new:2026-11-03Tavo Biotherapeutics · new in the registry NEW · Study of YKYY032 Injection in Adults With Hyperlipoproteinemia (a)https://saros.gcarosso.bio/#t=NCT07914660NCT07914660:new:2026-11-03Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. · new in the registry FIRMED · A Study of LY3867070 in Healthy Participantshttps://saros.gcarosso.bio/#t=NCT07021547NCT07021547:firmed:2026-11-03Eli Lilly and Company · primary completion: 2026-10 → 2026-09-30; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → COMPLETED; enrollment: 196 → 141 NEW · A Study to Evaluate the PK/PD and Safety of KL0011034 Injection in Healthy Non-Elderly and Elderly Trial Partihttps://saros.gcarosso.bio/#t=NCT07913048NCT07913048:new:2026-11-03Hunan Kelun Pharmaceutical Co., Ltd. · new in the registry NEW · Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatmenthttps://saros.gcarosso.bio/#t=NCT06374485NCT06374485:new:2026-11-03Lee's Pharmaceutical Limited · new in the registry FIRMED · NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancerhttps://saros.gcarosso.bio/#t=NCT06459869NCT06459869:firmed:2026-11-03Akamis Bio · primary completion: 2026-12-30 → 2027-01-30; enrollment: 30 → 33 SLIPPED · Pivotal Study of N-acetyl-L-leucine for CACNA1Ahttps://saros.gcarosso.bio/#t=NCT07221292NCT07221292:slipped:2026-11-03IntraBio Inc · primary completion: 2027-05-01 → 2028-05-01; status: RECRUITING → ACTIVE_NOT_RECRUITING SLIPPED · A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanchttps://saros.gcarosso.bio/#t=NCT06317311NCT06317311:slipped:2026-11-02GlaxoSmithKline · primary completion: 2026-07-15 → 2026-12-14 SLIPPED · Clinical Study of CS-001 as a Treatment for Canities (Grey Hair)https://saros.gcarosso.bio/#t=NCT06745336NCT06745336:slipped:2026-11-02Applied Biology, Inc. · primary completion: 2027-06-15 → 2027-12-15 SLIPPED · Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Diseasehttps://saros.gcarosso.bio/#t=NCT07696962NCT07696962:slipped:2026-11-02Xeno Holdings (US), LLC dba ChoironeX · primary completion: 2028-05-30 → 2028-06-30; status: NOT_YET_RECRUITING → RECRUITING FIRMED · First-in-human Study of Orally Administered KT-579 in Healthy Adult Participantshttps://saros.gcarosso.bio/#t=NCT07412288NCT07412288:firmed:2026-11-02Kymera Therapeutics, Inc. · primary completion: 2026-12 → 2026-08-22; date type: ESTIMATED → ACTUAL; status: RECRUITING → COMPLETED FIRMED · A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligohttps://saros.gcarosso.bio/#t=NCT07667569NCT07667569:firmed:2026-11-02Idorsia Pharmaceuticals Ltd. · primary completion: 2027-06 → 2027-06-28; status: NOT_YET_RECRUITING → RECRUITING FIRMED · A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005)https://saros.gcarosso.bio/#t=NCT07697625NCT07697625:firmed:2026-11-02Merck Sharp & Dohme LLC · primary completion: 2026-09-28 → 2026-10-06; date type: ESTIMATED → ACTUAL; status: RECRUITING → COMPLETED STATUS · Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Asshttps://saros.gcarosso.bio/#t=NCT07160608NCT07160608:status:2026-11-02Alexion Pharmaceuticals, Inc. · status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 75 → 78 STATUS · A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)https://saros.gcarosso.bio/#t=NCT07766499NCT07766499:status:2026-11-02Calixis Inc. · status: NOT_YET_RECRUITING → RECRUITING NEW · A Phase II Study Evaluating the Efficacy and Safety of Recombinant Human Truncated Plasmin Injection (JZB32) ihttps://saros.gcarosso.bio/#t=NCT07910630NCT07910630:new:2026-11-02Jiangsu Jingze Biopharmaceutical Co., Ltd. · new in the registry NEW · A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosishttps://saros.gcarosso.bio/#t=NCT07909655NCT07909655:new:2026-11-02Shanghai Huaota Biopharmaceutical Co., Ltd. · new in the registry SLIPPED · Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopeciahttps://saros.gcarosso.bio/#t=NCT06762548NCT06762548:slipped:2026-11-02Applied Biology, Inc. · primary completion: 2026-09-11 → 2028-03-11 STATUS · A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participahttps://saros.gcarosso.bio/#t=NCT07756580NCT07756580:status:2026-11-02AbbVie · primary completion: 2027-03 → 2027-02; status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 120 → 143 FIRMED · A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adhttps://saros.gcarosso.bio/#t=NCT04849728NCT04849728:firmed:2026-11-02Inventiva Pharma · primary completion: 2027-09-30 → 2026-09-29; date type: ESTIMATED → ACTUAL STATUS · Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLChttps://saros.gcarosso.bio/#t=NCT07754123NCT07754123:status:2026-11-02Jiangsu Hansoh Pharmaceutical Co., Ltd. · status: NOT_YET_RECRUITING → RECRUITING NEW · A Study to Investigate the Pharmacokinetics of JMKX003142 in Healthy Participants and Participants With Hepatihttps://saros.gcarosso.bio/#t=NCT07909070NCT07909070:new:2026-11-02Jemincare · new in the registry FIRMED · QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumorshttps://saros.gcarosso.bio/#t=NCT04898543NCT04898543:firmed:2026-11-02ImmunityBio, Inc. · primary completion: 2026-05-31 → 2026-02-02; date type: ESTIMATED → ACTUAL NEW · Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-relhttps://saros.gcarosso.bio/#t=NCT07908641NCT07908641:new:2026-11-02Amgen · new in the registry STATUS · A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through Menopausehttps://saros.gcarosso.bio/#t=NCT07829653NCT07829653:status:2026-11-02Astellas Pharma Inc · status: NOT_YET_RECRUITING → RECRUITING STATUS · Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemiahttps://saros.gcarosso.bio/#t=NCT07323095NCT07323095:status:2026-11-02Atom Therapeutics Co., Ltd · status: NOT_YET_RECRUITING → RECRUITING NEW · A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Diseasehttps://saros.gcarosso.bio/#t=NCT03737214NCT03737214:new:2026-11-02Idorsia Pharmaceuticals Ltd. · new in the registry FIRMED · A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patienhttps://saros.gcarosso.bio/#t=NCT06249919NCT06249919:firmed:2026-11-02Neuracle Science Co., LTD. · primary completion: 2026-05-31 → 2026-05-04; date type: ESTIMATED → ACTUAL; status: RECRUITING → COMPLETED; enrollment: 138 → 113 FIRMED · Drug-Drug Interaction Study of ABP-671 in Gout Patientshttps://saros.gcarosso.bio/#t=NCT07367971NCT07367971:firmed:2026-11-02Atom Therapeutics Co., Ltd · primary completion: 2026-07-31 → 2026-08-19; date type: ESTIMATED → ACTUAL; status: RECRUITING → COMPLETED; enrollment: 20 → 22 NEW · CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumorshttps://saros.gcarosso.bio/#t=NCT07909031NCT07909031:new:2026-11-02Crescent Biopharma, Inc. · new in the registry FIRMED · A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetehttps://saros.gcarosso.bio/#t=NCT06924320NCT06924320:firmed:2026-11-02Pfizer · primary completion: 2026-09-15 → 2026-09-29; date type: ESTIMATED → ACTUAL; status: RECRUITING → COMPLETED; enrollment: 381 → 201 FIRMED · A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Prevhttps://saros.gcarosso.bio/#t=NCT05852691NCT05852691:firmed:2026-11-02Hoffmann-La Roche · primary completion: 2026-10-19 → 2026-10-15; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → COMPLETED CHANGED · A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared https://saros.gcarosso.bio/#t=NCT06008093NCT06008093:changed:2026-11-02AstraZeneca · primary completion: 2026-10-23 → 2026-10-27 STATUS · Efficacy of a Multidomain Intervention on Lifestyle Risk Factors for Dementia Preventionhttps://saros.gcarosso.bio/#t=NCT06748625NCT06748625:status:2026-11-02LuciLab · status: ACTIVE_NOT_RECRUITING → COMPLETED; enrollment: 370 → 368 SLIPPED · A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapshttps://saros.gcarosso.bio/#t=NCT07123454NCT07123454:slipped:2026-11-02AstraZeneca · primary completion: 2028-03-01 → 2028-07-04; enrollment: 91 → 164; primary outcome text: Percentage of participants with dose-limiting toxicities (DLTs) → Percentage of participants with dose-limiting toxicities (DLTs) during the DLT period CHANGED · Phase 1 Study of Chlamydia Trachomatis mRNA Vaccine in Adults.https://saros.gcarosso.bio/#t=NCT06891417NCT06891417:changed:2026-11-02Sanofi · primary completion: 2028-01-03 → 2027-11-03; enrollment: 1560 → 80 NEW · A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234https://saros.gcarosso.bio/#t=NCT07911514NCT07911514:new:2026-11-02AstraZeneca · new in the registry FIRMED · An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Rhttps://saros.gcarosso.bio/#t=NCT03533283NCT03533283:firmed:2026-11-02Hoffmann-La Roche · primary completion: 2026-10-16 → 2026-10-22; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → COMPLETED CHANGED · A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adulhttps://saros.gcarosso.bio/#t=NCT06980428NCT06980428:changed:2026-11-02AstraZeneca · enrollment: 136 → 171 SLIPPED · ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumorshttps://saros.gcarosso.bio/#t=NCT05405595NCT05405595:slipped:2026-11-02Adagene Inc · primary completion: 2026-10-31 → 2027-06-30 CHANGED · Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinomahttps://saros.gcarosso.bio/#t=NCT07562152NCT07562152:changed:2026-11-02Immuneering Corporation · enrollment: 510 → 570 FIRMED · Safety and Efficacy Study of OMS906 in Patients With C3G and ICGNhttps://saros.gcarosso.bio/#t=NCT06209736NCT06209736:firmed:2026-11-02Omeros Corporation · primary completion: 2026-01 → 2026-04-14; date type: ESTIMATED → ACTUAL; status: RECRUITING → TERMINATED; enrollment: 20 → 3; why stopped: → The study was terminated for strategic reasons related to the molecule's recent acquisition SLIPPED · Clinical Study of mTOR Inhibitor as a Treatment for Grey Hair (Canities)https://saros.gcarosso.bio/#t=NCT07166354NCT07166354:slipped:2026-11-02Applied Biology, Inc. · primary completion: 2027-06-15 → 2027-10-15 NEW · Intratumoral Chlorine Dioxide Injection in Advanced Solid Tumorshttps://saros.gcarosso.bio/#t=NCT07911293NCT07911293:new:2026-11-02SunGlow Innovations LLC · new in the registry STATUS · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluhttps://saros.gcarosso.bio/#t=NCT07260877NCT07260877:status:2026-11-02Ventus Therapeutics U.S., Inc. · status: RECRUITING → ACTIVE_NOT_RECRUITING NEW · Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living Withttps://saros.gcarosso.bio/#t=NCT07908316NCT07908316:new:2026-11-02Amgen · new in the registry CHANGED · Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) https://saros.gcarosso.bio/#t=NCT06268886NCT06268886:changed:2026-11-02Bristol-Myers Squibb · primary completion: 2027-03-18 → 2026-12-17 CHANGED · A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Adhttps://saros.gcarosso.bio/#t=NCT07492680NCT07492680:changed:2026-11-02Bristol-Myers Squibb · enrollment: 260 → 254 SLIPPED · A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumhttps://saros.gcarosso.bio/#t=NCT06505824NCT06505824:slipped:2026-11-02Biokin (Shanghai) Biopharmaceutical Co., Ltd. · primary completion: 2026-08 → 2027-06; enrollment: 22 → 115 STATUS · Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participantshttps://saros.gcarosso.bio/#t=NCT07840729NCT07840729:status:2026-11-02Shanghai JMT-Bio Inc. · status: NOT_YET_RECRUITING → RECRUITING SLIPPED · A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Uhttps://saros.gcarosso.bio/#t=NCT06797297NCT06797297:slipped:2026-11-02Innovent Biologics (Suzhou) Co. Ltd. · primary completion: 2026-03-31 → 2026-12-31; status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 180 → 203 CHANGED · Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Achttps://saros.gcarosso.bio/#t=NCT06054113NCT06054113:changed:2026-11-02Amgen · primary completion: 2026-01-05 → 2026-01-06 SLIPPED · A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artehttps://saros.gcarosso.bio/#t=NCT07357675NCT07357675:slipped:2026-11-02EBI Anti Sepsis BV · primary completion: 2027-06-01 → 2027-10-01; status: NOT_YET_RECRUITING → RECRUITING FIRMED · Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vesselhttps://saros.gcarosso.bio/#t=NCT07354477NCT07354477:firmed:2026-11-02Qlaris Bio, Inc. · primary completion: 2026-10 → 2026-10-01; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → COMPLETED; enrollment: 14 → 9 NEW · A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 2 Study to Evaluate the Safety and Efficacy ofhttps://saros.gcarosso.bio/#t=NCT07909291NCT07909291:new:2026-11-02Cristcot LLC · new in the registry STATUS · Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expressionhttps://saros.gcarosso.bio/#t=NCT07809906NCT07809906:status:2026-11-02Orum Therapeutics USA, Inc. · status: NOT_YET_RECRUITING → RECRUITING SLIPPED · A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumorshttps://saros.gcarosso.bio/#t=NCT06349811NCT06349811:slipped:2026-11-02Biokin (Shanghai) Biopharmaceutical Co., Ltd. · primary completion: 2026-05 → 2027-06 NEW · Clinical Study of DA-002 and DA-005 as a Treatment for Hair Losshttps://saros.gcarosso.bio/#t=NCT06501924NCT06501924:new:2026-11-02Applied Biology, Inc. · new in the registry NEW · A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable Schizophrenihttps://saros.gcarosso.bio/#t=NCT07908680NCT07908680:new:2026-11-02Novartis Pharmaceuticals · new in the registry SLIPPED · A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)https://saros.gcarosso.bio/#t=NCT06985147NCT06985147:slipped:2026-11-02Disc Medicine, Inc · primary completion: 2027-02 → 2027-07 FIRMED · A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension https://saros.gcarosso.bio/#t=NCT07073820NCT07073820:firmed:2026-11-02Pfizer · primary completion: 2028-08-24 → 2026-10-09; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → TERMINATED; why stopped: → The study terminated due to a business decision and was not based on any safety and/or efficacy concerns. NEW · Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatichttps://saros.gcarosso.bio/#t=NCT05607550NCT05607550:new:2026-11-02ArriVent BioPharma, Inc. · new in the registry CHANGED · A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancerhttps://saros.gcarosso.bio/#t=NCT07217301NCT07217301:changed:2026-11-02Takeda · enrollment: 600 → 1200; primary outcome text: Global Part: Confirmed Objective Response Rate (cORR) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors → Squamous NSCLC Part: Confirmed Objective Response Rate (cORR) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid CHANGED · A Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancerhttps://saros.gcarosso.bio/#t=NCT07777211NCT07777211:changed:2026-11-02Beijing Gene Key Life Technology Co., Ltd · primary outcome text: Incidence of Dose-Limiting Toxicities → Phase I: Incidence of Dose-Limiting Toxicities NEW · A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanhttps://saros.gcarosso.bio/#t=NCT05170204NCT05170204:new:2026-11-02Hoffmann-La Roche · new in the registry NEW · β-Thalassemia Treatment With KL003 Cell Injectionhttps://saros.gcarosso.bio/#t=NCT06280378NCT06280378:new:2026-11-02Kanglin Biotechnology (Hangzhou) Co., Ltd. · new in the registry SLIPPED · Safety of AM-928 Infusion in Advanced Solid Tumorshttps://saros.gcarosso.bio/#t=NCT05687682NCT05687682:slipped:2026-11-02AcadeMab Biomedical Inc. · primary completion: 2026-06 → 2027-06 SLIPPED · Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participanthttps://saros.gcarosso.bio/#t=NCT06959706NCT06959706:slipped:2026-11-02Tagworks Pharmaceuticals BV · primary completion: 2026-09 → 2027-10; enrollment: 50 → 90 SLIPPED · AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRChttps://saros.gcarosso.bio/#t=NCT06245915NCT06245915:slipped:2026-11-02Arsenal Biosciences, Inc. · primary completion: 2026-03-31 → 2026-12-31 REGULATORY · Bridgebio Pharma, Inc. · infigratinib · 2027-02-04https://saros.gcarosso.bio/#tab=fdaBBIO:regulatory:2026-10-29Bridgebio Pharma, Inc. · 2027-05-08 → 2027-02-04 REGULATORY · Cormedix Inc. · pdufa · 2027-12-31https://saros.gcarosso.bio/#tab=fdaCRMD:regulatory:2026-10-19Cormedix Inc. · 2027-03-31 → 2027-12-31 REGULATORY · Aquestive Therapeutics, Inc. · Anaphylm · 2027-03-16https://saros.gcarosso.bio/#tab=fdaAQST:regulatory:2026-10-15Aquestive Therapeutics, Inc. · 2027-03-29 → 2027-03-16 REGULATORY · Cogent Biosciences, Inc. · bezuclastinib · 2026-12-30https://saros.gcarosso.bio/#tab=fdaCOGT:regulatory:2026-08-10Cogent Biosciences, Inc. · 2026-11-30 → 2026-12-30 STATUS · FS120 Phase 1/1b Study in Patients With Advanced Malignancieshttps://saros.gcarosso.bio/#t=NCT04648202NCT04648202:status:2025-06-27invoX Pharma Limited · status: ACTIVE_NOT_RECRUITING → UNKNOWN STATUS · Efficacy and Safety of ENN0403 in Patients At High Risk for Acute Kidney Injury Following Elective Cardiac Surhttps://saros.gcarosso.bio/#t=NCT06632613NCT06632613:status:2025-01-13EnnovaBio · status: RECRUITING → UNKNOWN STATUS · A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophahttps://saros.gcarosso.bio/#t=NCT06474468NCT06474468:status:2025-01-03Shanghai Hengrui Pharmaceutical Co., Ltd. · status: RECRUITING → UNKNOWN STATUS · A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthmahttps://saros.gcarosso.bio/#t=NCT06637254NCT06637254:status:2024-12-24Haisco Pharmaceutical Group Co., Ltd. · status: ENROLLING_BY_INVITATION → UNKNOWN STATUS · Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellulahttps://saros.gcarosso.bio/#t=NCT06558227NCT06558227:status:2024-12-16Suzhou Zelgen Biopharmaceuticals Co.,Ltd · status: RECRUITING → UNKNOWN STATUS · Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Brhttps://saros.gcarosso.bio/#t=NCT06222879NCT06222879:status:2024-11-25Shandong Suncadia Medicine Co., Ltd. · status: RECRUITING → UNKNOWN STATUS · A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophreniahttps://saros.gcarosso.bio/#t=NCT06649214NCT06649214:status:2024-10-21Qilu Pharmaceutical Co., Ltd. · status: NOT_YET_RECRUITING → UNKNOWN STATUS · A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®https://saros.gcarosso.bio/#t=NCT06633783NCT06633783:status:2024-10-09Hangzhou Jiuyuan Gene Engineering Co. Ltd., · status: NOT_YET_RECRUITING → UNKNOWN